Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status

Pharmacogenetics

Volumn 13, Issue 5, 2003, Pages 291-295

  Jarvik, Gail P ^a,b   Jampsa, Rachel ^a   Richter, Rebecca J ^a   Carlson, Chris S ^a   Rieder, Mark J ^a   Nickerson, Deborah A ^a   Furlong, Clement E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Activity; Coding; Functional; Paraoxonase; Sequencing

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GLUCOCORTICOID; ORGANOPHOSPHATE PESTICIDE; STATIN;

AMINO ACID SUBSTITUTION; AMPLICON; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DETOXIFICATION; GENE SEQUENCE; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STOP CODON;

ARYLDIALKYLPHOSPHATASE; CODON, NONSENSE; HUMANS; KINETICS; MUTATION, MISSENSE; ORGANOPHOSPHORUS COMPOUNDS; PARAOXON;

EID: 0038579858     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200305000-00009     Document Type: Article

References (13)

1. Jarvik G, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-2447.
2. Mackness B, Gershan KD, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21:1451-1457.
3. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19:330-335.
4. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3:73-76.
5. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608.
6. Brophy V, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Promoter polymorphism effects on paraoxonase (PON1) expression. Am J Hum Genet 2001; 68:1428-1436.
7. Brophy V, Hastings MD, Clendenning JB, Richter R, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001; 11:77-84.
8. Richter R, Furlong CE, Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745-753.
9. Miller S, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16:1215.
10. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000; 150:295-298.
11. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophy Res Commun 1997; 236:289-293.
12. James R, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary heart disease. Circulation 2000; 101:2252-2257.
13. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, Marrugat J. Effect of simvastatin therapy on paraoxonase activity and related properties in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000; 19:1340-1347.